Breakthrough AI-driven drug discovery

Better tech for better patient outcomes

Entos pioneered quantum AI, revolutionizing drug discovery by deepening the exploration of chemical space

We illuminate novel chemical matter to unlock better development candidates.
‍
We drive to clinic faster through our high-throughput discovery platform.

Our pipeline Our technology

Accelerated molecular design

Powerful simulations

OrbNet uses quantum features to
produce 1000x acceleration in
quantum mechanics calculations

Data-efficient ML

Proprietary quantum features lead to
100x reduction in data requirements
for ML property prediction

Automated chemistry

Automated synthesis and experiment
guided by ML, driving continuous
model improvement

Trusted by

Our work

Entos in the news

Entos Presents Latest AI-Driven Drug Discovery Advances at NeurIPS 2022

Entos Head of Business Development Mary Anderson among top 25 healthcare technology leaders of San Diego for 2022

Chao Zhang joins Entos as Chief Scientific Officer

Chao's recruitment heralds the transition of Entos from a discovery-stage to a clinical-stage AI-driven biotech

Entos in Forbes AI50

Entos selected by Forbes Magazine for 2022 list of groundbreaking artificial intelligence companies

Entos Appoints Nicholas A. Saccomano, Ph. D., to its Scientific Advisory Board

Nick brings 35 years of R&D experience across a broad spectrum of therapeutic areas and modalities

Entos Mourns the Loss of Board Member Naren Gupta

A statement from the Entos management team and Board of directors in memoriam of Naren Gupta





Entos Presents Latest AI-Driven Drug Discovery Advances at NeurIPS 2022

Entos Head of Business Development Mary Anderson among top 25 healthcare technology leaders of San Diego for 2022

Entos-Caltech-NVIDIA Collaboration

Advances reported in geometric deep learning for computational chemistry in Proceedings of the National Academy of Science USA

Chao Zhang joins Entos as Chief Scientific Officer

Chao's recruitment heralds the transition of Entos from a discovery-stage to a clinical-stage AI-driven biotech

Entos in Forbes AI50

Entos selected by Forbes Magazine for 2022 list of groundbreaking artificial intelligence companies

Entos Appoints Nicholas A. Saccomano, Ph. D., to its Scientific Advisory Board

Nick brings 35 years of R&D experience across a broad spectrum of therapeutic areas and modalities





Entos Presents Latest AI-Driven Drug Discovery Advances at NeurIPS 2022

Entos Head of Business Development Mary Anderson among top 25 healthcare technology leaders of San Diego for 2022

Entos-Caltech-NVIDIA Collaboration

Advances reported in geometric deep learning for computational chemistry in Proceedings of the National Academy of Science USA

Chao Zhang joins Entos as Chief Scientific Officer

Chao's recruitment heralds the transition of Entos from a discovery-stage to a clinical-stage AI-driven biotech

Entos in Forbes AI50

Entos selected by Forbes Magazine for 2022 list of groundbreaking artificial intelligence companies

Entos Appoints Nicholas A. Saccomano, Ph. D., to its Scientific Advisory Board

Nick brings 35 years of R&D experience across a broad spectrum of therapeutic areas and modalities





Our Mission

Entos is revolutionizing drug discovery through technology

Our team collaborates to build next-generation technologies

Our goal is to empower each other to do our best work

Our vision is faster, safer therapeutics discovery

Jeanne Grover

Director, Finance & Operations

Shane Yost

Applications Scientist

Elizabeth Ter Sahakyan

Lead Product Dev Engineer

Wallace Derricotte

Research Scientist

Feizhi Ding

Senior Software Engineer

Join us as we change the game in drug discovery

We are rapidly expanding our team and are hiring experts in medicinal chemistry, discovery biology, automation, and machine learning.

View Openings